Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 15, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details specific share movements on May 11, 2006, involving the SmithKline Beecham Employee Benefit Trust ("the Trust"):
- Share Sale: 595 Ordinary shares were sold on behalf of participants in the GlaxoSmithKline Annual Investment Plan at a price of GBP 15.43 per share.
- Share Transfer: 845 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
Management Commentary and Risks
The Trust is described as a discretionary fund where all non-US employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that Director Mr. J Heslop holds an interest in the shares held in the fund in the same manner as other non-US employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the reported transactions.
- Confirm the current share price relative to the GBP 15.43 transaction price reported for May 11, 2006.
- Review the full composition of the Trust to understand the extent of Director J Heslop's indirect interest.